
Autolus is a Nasdaq-listed immunotherapy company developing advanced T-cell therapies. Following a brand refresh, the business required a new website that reflected its post-IPO maturity while supporting complex scientific, investor and recruitment content.
I was responsible for UI design, component structuring and interaction specification across the platform.

The site needed to communicate dense and technical information, from clinical pipeline progression to modular technology architecture and investor updates. The challenge was to present this material with authority, while avoiding visual overload.
Working from the established creative direction, I designed a reusable component set aligned to Umbraco’s modular framework. Rather than fixed page templates, the platform was structured around adaptable content blocks capable of scaling as the organisation evolved.
Bespoke tabular layouts were created for scientific data and pipeline presentation, mapping programmes across discovery, pre-clinical and clinical phases through clearly bounded progression bars. Colour coding reinforced therapeutic categories while preserving legibility. On smaller screens, the structure was reconfigured to maintain hierarchy and readability without compressing information into unusable tables.
Filterable publication layouts, annotated carousel modules and a full-screen navigation pattern were designed to accommodate unpredictable content lengths while maintaining consistent grid logic and pace.

Interaction behaviours were purposeful and restrained. Timeline and carousel components relied on controlled positional and opacity shifts rather than heavy animation. Hover states were deliberate and minimal, giving affordance without distraction.

The result is a clear, credible and scalable digital platform that reflects Autolus’s scientific rigour and commercial maturity. The component-based structure provides flexibility for ongoing growth while maintaining consistency across devices.